Can an open drug discovery model find a solution for rare brain cancers in children?

By | 2018-08-03T11:45:44+00:00 August 1st, 2018|

Can an open drug discovery model find a solution for rare brain cancers in children? Dr. Aled Edwards OICR-funded drug discovery project’s unique ‘open science’ business model is accelerating the search for a solution to lethal pediatric brain cancers. Diffuse intrinsic pontine glioma (DIPG) is a lethal and inoperable brain cancer with a median survival [...]

Reaction Biology Joins the Fight Against DIPG with M4K Pharma [News Release]

By | 2018-05-24T14:37:37+00:00 May 24th, 2018|

  Reaction Biology Joins the Fight Against DIPG with M4K Pharma [News Release] Malvern, PA- May 23, 2018. Reaction Biology Corporation (“RBC”), a leading contract research organization providing early stage drug discovery services, announced that it has partnered with M4K Pharma (“M4K”), an open science drug discovery and development company, in the fight against diffuse [...]

Editorial: Research community ready for Open Source Drug Discovery

By | 2018-05-09T11:58:28+00:00 February 28th, 2018|

Editorial: Research community ready for Open Source Drug Discovery In an Editorial to the Canadian Science Policy Centre, Drs. Aled Edwards and Aidan Hollis describe the need for Open Source Drug Discovery to address the inefficiencies in developing new drugs and the resulting exorbitant prices of new medicines. The support for M4K [...]

OICR’s Cancer Therapeutics Innovation Pipeline initiative funds M4K’s ALK2 program for DIPG as part of the inaugural set of projects

By | 2018-05-09T11:45:36+00:00 December 4th, 2017|

OICR's Cancer Therapeutics Innovation Pipeline initiative funds M4K's ALK2 program for DIPG as part of the inaugural set of projects The Ontario Institute for Cancer Research (OICR) announced its Cancer Therapeutics Innovation Pipeline (CTIP) initiative and the first 10 projects selected for the inaugural round of funding. CTIP will support the [...]

U of T News covers M4K Pharma’s innovative business model for drug discovery

By | 2018-05-09T11:55:22+00:00 November 3rd, 2017|

Making medicine, not money: How one U of T researcher's startup is rethinking Big Pharma's business model M4K Pharma's first target is a rare childhood brain cancer that's just as deadly as it was 50 years ago From U of T News (November 3, 2017) The latest medical innovation to [...]